Amox clav for ear infection

RESULTS: The groups were similar at baseline, and 93.1% followed up at 28 days.

In the intention-to-treat population (920 patients), clinical success at 28 days was equivalent among AZM-3 (71.5%), AZM-6 (74.1%), and AMC (71.5%). Subjects treated with AMC reported a higher incidence of treatment-related adverse events than AZM-3 (51.1% vs 31.1%; P =.001; number needed to treat [NNT]=5) or AZM-6 (51.1% vs 37.6%; P =.001; NNT=7).

Diarrhea was the most frequently reported adverse event, occurring in 17% to 21% of patients treated with azithromycin and 32% of patients treated with AMC. Compliance was significantly better in the AZM groups compared with the AMC group (AZM-3: 99.2%; AZM-6: 93.9%; and AMC: 82.1%). Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of

Acute

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Listing a study does not mean it has been evaluated by the U.S. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

Study Details Tabular View No Results Posted Disclaimer How to Read a Study Record.

To evaluate the clinical efficacy of pristinamycin at a dose of 2g x 2/day for 2 days then 1g x 3/day for 5 to 7 days versus amoxicillin 1g x3 /day for 7 to 9 days, 5 to 9 days after the end of treatment.

To evaluate the clinical efficacy in a subpopulation bacteriologically documented at inclusion and according to procalcitonin level.

To evaluate the efficacy of treatments against pneumococcus.

To evaluate the rate of relapse and mortality 30±2 days after treatment is started.

Condition or disease Intervention/treatment Phase Pneumonia Drug: PRISTINAMYCIN XRP7263 Drug: Amoxicillin Drug: Amoxicillin Placebo Drug: PRISTINAMYCIN Placebo Phase 4.

Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 500 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Multi-centre, Non-inferiority, Randomized, Double-blind, Phase IV Study Comparing Pristinamycin (2g x 2 Per Day for 2 Days Then 1g x 3 Per Day for 5 to 7 Days) to Amoxicillin (1g x 3 Per Day) for 7 to 9 Days in Adults With Acute Community Acquired Pneumonia With a PORT Score of II or III Actual Study Start Date : April 30, 2015 Estimated Primary Completion Date : May 31, 2021 Estimated Study Completion Date : May 31, 2021.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No. Male or female more than 18 years old with a presumed bacterial acute community acquired pneumonia presenting a PORT score of II or III (Fine II or III). The acute community acquired pneumonia is defined by: Pulmonary x-ray (carried out within the 48 hours prior to randomization) showing new lobar or multilobar infiltrates. At least 4 functional and/or clinical symptoms from among the following: Fever characterized by a temperature of more than 38.5 at least once within 24h prior to inclusion. Tachypnoea Chest pain A characteristic sign on percussion and/or auscultation associated with a pulmonary condensation focus.

Patients having received systemic antibiotic therapy of over 24 hours within the week preceding the start of study treatment.

Associated neoplasm 875 125 pill for tooth infection (active cancer [of whatever type, solid or haematological] or diagnosed within the year other than basocellular skin cancer). Severe or very severe chronic obstructive pulmonary disease (COPD) (GOLD3 and GOLD4). History of bacterial pneumonia in the past 12 months.

Bronchopulmonary diseases likely to interfere with the assessment of the therapeutic response. Known hypersensitivity to streptogramins, penicillin and other betalactamines or excipients of the treatments studied. History of severe skin reaction after taking pristinamycin or amoxicillin. Kidney disease (chronic kidney failure or creatinine clearance ?30 mL/minute). Patients treated with allopurinol, colchicine, immunosuppressants (cyclosporin, tacrolimus, mycophenolate mofetil, methotrexate, biotherapies) oral anticoagulants in the previous 6 months or during the study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

AMOXIL (amoxicillin) Capsules, Tablets, or Powder for Oral Suspension. Formulations of

AMOXIL

It may be represented structurally as: The amoxicillin molecular formula is C 16 H 19 N 3 O 5 S•3H 2 O, and the molecular weight is 419.45. Capsules : Each capsule of AMOXIL, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg amoxicillin as the trihydrate. The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500-mg capsule are imprinted with AMOXIL and 500.

40, gelatin, magnesium stearate, and titanium dioxide. Tablets : Each tablet contains 500 mg or 875 mg amoxicillin as the trihydrate.

Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively. Inactive ingredients: Colloidal silicon dioxide, crospovidone, FD&C Red No. 30 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide.

Powder for Oral Suspension : Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Each 5 mL of the 125-mg reconstituted suspension contains 0.11 mEq (2.51 mg) of sodium. Each 5 mL of the 200-mg reconstituted suspension contains 0.15 mEq (3.39 mg) of sodium.

Each 5 mL of the 250-mg reconstituted suspension contains 0.15 mEq (3.36 mg) of sodium; each 5 mL of the 400-mg reconstituted suspension contains 0.19 mEq (4.33 mg) of sodium. 3, flavorings, silica gel, sodium benzoate, sodium citrate, sucrose, and xanthan gum. AMOXIL® is indicated in the treatment of infections due to susceptible (ONLY ?-lactamase–negative) isolates of Streptococcus species. (?-and ?-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae .

AMOXIL® is indicated in the treatment of infections due to susceptible (ONLY ?-lactamase–negative) isolates of Escherichia coli, Proteus mirabilis , or Enterococcus faecalis . AMOXIL® is indicated in the treatment of infections due to susceptible (ONLY ?-lactamase–negative) isolates of Streptococcus spp. (?-and ?-hemolytic isolates only), Staphylococcus spp., or E. AMOXIL® is indicated in the treatment of infections due to susceptible (ONLY ?-lactamase–negative) isolates of Streptococcus spp.

Triple Therapy for Helicobacter Pylori with Clarithromycin and Lansoprazole. AMOXIL, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.

pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H.

pylori has been shown to reduce the risk of duodenal ulcer recurrence. AMOXIL, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected.

(See the clarithromycin package insert , Microbiology .) Eradication of H.

pylori has been shown to reduce the risk of duodenal ulcer recurrence. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXIL (amoxicillin) and other antibacterial drugs, AMOXIL should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dosing For Adult And Pediatric Patients > 3 Months Of Age.

Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.

It is recommended that there be at least 10 days' treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever.

In some infections, therapy may be required for several weeks.

It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy. Table 1: Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age Infection Severity a Usual Adult Dose Usual Dose for Children > 3 Months b Ear/Nose/Throat Skin/Skin Structure Genitourinary Tract Mild/Moderate 500 mg every 12 hours or 250 mg every 8 hours 25 mg/kg/day in divided doses every 12 hours or 20 mg/kg/day in divided doses every 8 hours Severe 875 mg every 12 hours or 500 mg every 8 hours 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours Lower Respiratory Tract Mild/Moderate or Severe 875 mg every 12 hours or 500 mg every 8 hours 45 mg/kg/day in divided doses every 12 hours or 40 mg/kg/day in divided doses every 8 hours a Dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections.

b The children's dosage is intended for individuals whose weight is less than 40 kg. Children weighing 40 kg or more should be dosed according to the adult recommendations.

Dosing In Neonates And Infants Aged ? 12 Weeks ( ? 3 Months) Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.

It is recommended that there be at least 10 days' treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever. Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of AMOXIL is 30 mg/kg/day divided every 12 hours.

There are currently no dosing recommendations for pediatric patients with impaired renal function.

The recommended adult oral dose is 1 gram AMOXIL, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. The recommended adult oral dose is 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.

Please refer to clarithromycin and lansoprazole full prescribing information.

Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Severely impaired patients with a glomerular filtration rate of Strength Bottle Size Amount of Water Reauired for Reconstitution Oral Suspension 125 mg/5 mL 80 mL 62 mL 100 mL 78 mL 150 mL 116 mL Oral Suspension 200 mg/5 mL 50 mL 39 mL 75 mL 57 mL 100 mL 76 mL Oral Suspension 250 mg/5 mL 80 mL 59 mL 100 mL 74 mL 150 mL 111 mL Oral Suspension 400 mg/5 mL 50 mL 36 mL 75 mL 54 mL 100 mL 71 mL.

After reconstitution, the required amount of suspension should be placed directly on the child's tongue for swallowing.

Alternate means of administration are to add the required amount of suspension to formula, milk, fruit juice, water, ginger ale, or cold drinks. These preparations should then be taken immediately. Any unused portion of the reconstituted suspension must be discarded after 14 days.

Each capsule of AMOXIL, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg amoxicillin as the trihydrate. The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500 mg capsule are imprinted with AMOXIL and 500.

Each tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively. 125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL, 400 mg/5 mL. Each 5 mL of reconstituted strawberry-flavored suspension contains 125 mg amoxicillin as the trihydrate. Each 5 mL of reconstituted bubble-gumflavored suspension contains 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Capsules: Each capsule of AMOXIL, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg amoxicillin as the trihydrate. The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500 mg capsule are imprinted with AMOXIL and 500. NDC 43598-025-01 Bottles of 100 NDC 43598-025-05 Bottles of 500.

NDC 43598-005-01 Bottles of 100 NDC 43598-005-05 Bottles of 500.

Tablets: Each tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively.

NDC 43598-024-01 Bottles of 100 NDC 43598-024-05 Bottles of 500.

NDC 43598-019-01 Bottles of 100 NDC 43598-019-14 Bottles of 20. Powder for Oral Suspension: Each 5 mL of reconstituted strawberry-flavored suspension contains 125 mg amoxicillin as the trihydrate. Each 5 mL of reconstituted bubble-gum-flavored suspension contains 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate.

NDC 43598-022-80 80-mL bottle NDC 43598-022-52 100-mL bottle NDC 43598-022-53 150-mL bottle.

NDC 43598-023-50 50-mL bottle NDC 43598-023-51 75-mL bottle NDC 43598-023-52 100-mL bottle.

NDC 43598-009-80 80-mL bottle NDC 43598-009-52 100-mL bottle NDC 43598-009-53 150-mL bottle.

NDC 43598-007-50 50-mL bottle NDC 43598-007-51 75-mL bottle NDC 43598-007-52 100-mL bottle.

Store at or below 20° C (68° F) -250 mg and 500 mg Capsules and 125 mg and 250 mg unreconstituted powder.

Store at or below 25° C (77° F) -500 mg and 875 mg Tablets and 200 mg and 400 mg unreconstituted powder.

The following are discussed in more detail in other sections of the labeling: Anaphylactic reactions [see WARNINGS AND PRECAUTIONS ] CDAD [see WARNINGS AND PRECAUTIONS ] Clinical Trials Experience.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.